Skip to main content
. 2006 Dec;2(4):327–340. doi: 10.2147/vhrm.2006.2.4.327

Figure 1.

Figure 1

Efficacy of olmesartan medoxomil (OLM) at 2- (Sankyo Pharma GmbH 2002) and 8- (Puchler et al 2001) weeks in a pooled analysis of 7 placebo-controlle-dtrials: primary efficacy endpoints.

a) The proportion of patients achieving a target sitting systolic blood pressure ≤140 mmHg

b) The proportion of patients achieving a target sitting dystolic blood pressure (DBP) of ≤90 mmHg.

c) Mean change from baseline in sitting DBP.

Note: *p<0.001